Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approves lisdexamfetamine dimesylate as an Original Application (ANDA) for Teva Pharmaceuticals, providing a generic option for the ADHD…
-
FDA approval · 2023-08-24FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Golden State Medical Supply, Inc.)
FDA approved a supplemental ANDA from Golden State Medical Supply, Inc. to manufacture a generic combination of dextroamphetamine saccharate…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children [Phase 4]
A Phase 4 safety and tolerability study of Adhansia XR extended-release capsules in children with ADHD was terminated; results posted in 202…
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant [NA]
A completed clinical trial evaluating a software intervention as adjunctive treatment for ADHD, with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: Atomoxetine PBPK-PD Clinical Study
Clinical trial update for Atomoxetine PBPK-PD study in ADHD has completed and results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Irritability in Children With ADHD and Emotion Dysregulation [Phase 4]
Phase 4 trial update evaluating irritability in children with ADHD and emotion dysregulation has completed.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 4]
Phase 4 real-world evidence study on duration of effect for Adhansia XR in ADHD has been terminated with results posted.
-
FDA approval · 2023-07-24FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for dexmethylphenidate hydrochloride from Sun Pharmaceutical Industries, indicating a modification/ …
-
FDA approval · 2023-07-20FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Dexmethylphenidate hydrochloride from Nivagen Pharmaceuticals, Inc., relating to an approved gen…
-
FDA approval · 2023-07-12FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved the supplemental application for methylphenidate hydrochloride from Actavis Pharma, Inc., resulting in an approved supplemental…
-
FDA approval · 2023-07-10FDA Approved: CLONIDINE HYDROCHLORIDE — Supplemental Application (Xiamen LP Pharmaceutical Co., Ltd.)
FDA approved a supplemental ANDA for clonidine hydrochloride from Xiamen LP Pharmaceutical Co., Ltd., granting approval for a generic clonid…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening [Phase 3]
Phase 3 study assessing the duration and efficacy of MYDAYIS on adult ADHD symptoms and executive function across the day and into early eve…
-
CLINICAL_TRIALS research · 2023-06-28Clinical Trial Update: Virtual Reality to Improve Social Perspective Taking [NA]
Clinical trial update on using virtual reality to improve social perspective taking in youth with conduct disorders and related behavioral c…
-
FDA approval · 2023-06-23FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
FDA approval of a supplemental application for a methylphenidate hydrochloride product from Lupin Pharmaceuticals, Inc.
-
FDA approval · 2023-06-22FDA Approved: AMPHETAMINE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's original application for generic Amphetamine, enabling marketing of amphetamine as a stimulant for ADHD and narcolepsy.
-
FDA approval · 2023-05-08FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (KVK-TECH, INC)
FDA approved a supplemental application for Dexmethylphenidate hydrochloride from KVK-TECH, INC., related to an existing generic product.
-
FDA approval · 2023-05-08FDA Approved: ATOMOXETINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals’ supplemental application for atomoxetine, enabling a generic product. Atomoxetine is used to treat …
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance [Phase 4]
A Phase 4 clinical trial assessing how expectations, medication, and placebo influence objective and self-rated performance in ADHD and Subs…
-
FDA approval · 2023-04-19FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride (LA), expanding access to this extended-release ADHD medicatio…
-
FDA approval · 2023-04-07FDA Approved: ATOMOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for atomoxetine by Teva Pharmaceuticals USA, Inc., indicating an updated labeling for the generic pr…
-
CLINICAL_TRIALS trial_result · 2023-04-06Clinical Trial Update: Effect of Probiotics on ADHD [Phase 3]
Phase 3 clinical trial assessing the effect of probiotics on attention-deficit/hyperactivity disorder (ADHD) has been completed.
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders [NA]
A completed clinical trial using a SMART design to improve sleep disturbances in adolescents with autism spectrum disorder and ADHD.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: Intervention for Teens With ADHD and Substance Use [Phase 3]
Phase 3 trial update for an intervention targeting teens with ADHD and substance use has been terminated; results posted.
-
FDA approval · 2023-03-07FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva's generic amphetamine salt product, adding four amphetamine salt components (dextroamphetam…
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Improving ADHD Teen Driving [NA]
A completed clinical trial update on improving teen driving in ADHD populations; results posted in 2023.